Market Intelligence Resource | August 28, 2024

FDA Clearance Letter For Rejoyn Prescription Digital Therapeutic

The U.S. Food and Drug Administration (FDA) issued the letter on March 30, 2024, to Otsuka America Pharmaceutical, Inc. It grants market clearance for Rejoyn, a prescription digital therapeutic smartphone app for the treatment of major depressive disorder (MDD) as an adjunct to clinician-managed outpatient care for adults . . .

Want To Read More? Log In Or Become A Paid Member

Resource Available For Paid OPEN MINDS Circle Members Only

Not a paid member? Don't miss out! Sign up today and receive unlimited organizational access to all OPEN MINDS strategic advice, market intelligence, and management best practices – over 250,000 resources!

If you are already a paid member, log in to your account to access this resource and more. If you are a free member, you will need to upgrade to a paid membership before accessing this resource.

Become A Paid Member

If you are not yet a paid member, learn more about the OPEN MINDS Circle Market Intelligence Service Membership on our website, reach out to our team at info@openminds.com, or call us at 877-350-6463.

About

Contact

FDA Clearance Letter For Rejoyn Prescription Digital Therapeutic

Tagged As:

About

Contact

Markets

Services

Customers

Publications

Markets

Topics

Executive Institutes

Professional Development Programs

Tools

Assessments

Tagged As: